Health
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological disorders, to incorporate quantitative electroencephalography (EEG) measurements into two of Harmony’s Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. The collabo
About this update from Harmony Biosciences Holdings, Inc.
[{"type":"image","alt":"Beacon Biosignals","displaySize":"","headline":null,"caption":"Beacon Biosignals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/22419fa35f698e2d00ce3c9551d9cc35"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ogkUFBXpKsOSb_iazYoaGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/22419fa35f698e2d00ce3c9551d9cc35","width":300,"height":76}},"lazy":false},{"type":"text","content":"BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological disorders, to incorporate quantitative electroencephalography (EEG) measurements into two of Harmony’s Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia.","length":488,"tagName":"p"},{"type":"text","content":"The collaboration will support Harmony’s primary objective of assessing excessive daytime sleepiness (EDS) by complementing traditional patient-reported outcomes, such as the Epworth Sleepiness Scale (ESS), with objective sleep EEG data.","length":237,"tagName":"p"},{"type":"text","content":"Through this study, Beacon’s FDA 510(k)-cleared Waveband EEG headband and AI-driven algorithms will be used to capture at-home brain data across consecutive nights of sleep. Additionally, it will assess daytime sleepiness with continuous EEG data enabled by the Waveband’s wireless, low-profile design. By continuously measuring nighttime sleep quality as well as daytime naps, Beacon’s technology provides a more precise view of hypersomnolence in real-world environments.","length":473,"tagName":"p"},{"type":"text","content":"“This collaboration with Harmony represents an important step toward bringing quantitative sleep neurophysiology into late-stage drug development,” said David Matthews, PhD, President of Life Sciences at Beacon Biosignals. “Measuring objective sleep EEG data alongside subjective endpoints like patient-reported outcomes improves the precision and interpretability of treatment outcomes, and we expect it will accelerate the path toward better therapies for people living with hyp...